Baillie Gifford has launched a UK OEIC Health Innovation fund, with a portfolio comprised of 35 listed mid-size high-growth companies in the fields of pioneering therapies, diagnostics and digital technology.
The new OEIC will sit alongside the Dublin-registered UCITS fund which was made available to external investors in April this year, having launched on 1 October 2018. Both funds are managed by a team of three: Julia Angeles, Rose Nguyen and Marina Record, plus an advisory group of five other investment managers. Baillie Gifford reduces fees on Dow and Ross's global equity income funds Total assets under management for the Baillie Gifford Health Innovation UCITS fund are currently $113m (£83m), with an additional $206m in segregated mandates. Since inception, the UCITS fund has r...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
